Bio-Path Holdings (BPTH) Provides 2025 Clinical and Operational Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Bio-Path Holdings (BPTH) Provides 2025 Clinical and Operational Update

Bio-Path Holdings Provides 2025 Clinical and Operational Update

January 10, 2025 7:00 AM EST

Advancing Multiple Programs in Areas of Significant Unmet Medical Need

Several Milestones Across Clinical Development Pipeline Expected in 2025

HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides a clinical development and operational update for 2025.

The important work we conducted throughout 2024 has led us into what we believe is... More